Girod, Anne
Ludwig-Maximilians-Universität München
4 papers on CoChat
Most cited papers
- Verified
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine
Virus-based gene therapy researchRNA Interference and Gene Delivery
Cited by 405
- Verified
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity
Girod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology
Virus-based gene therapy researchParvovirus B19 Infection Studies
Cited by 354
- Verified
Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2–Cell Interaction and Neutralization of AAV-2 Infection
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology
Virus-based gene therapy researchViral Infections and Immunology Research
Cited by 273
- Verified
Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies
Huttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M. (2003) · Gene Therapy
Virus-based gene therapy researchRNA Interference and Gene Delivery
Cited by 124
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free